Dialyfix Email Formats

About Dialyfix

More than 2 million patients suffering from end-stage renal disease (ESRD) need hemodialysis (HD) for treatment. Currently, the preferred vascular access method for HD is the arteriovenous fistula (AVF). However, the AVF is the cause of several complications: 30%-60% non-maturation rate, stenosis, thrombosis, infections; 30% of HD patients are hospitalized following post-procedural AVF complications including AVF failure. Health care expenditure related to ESRD: more than 34 billion USD in the United States alone, a significant portion of this expense being related to HD and to creation and maintenance of AVFs. Dialyfix® is a MedTech startup that develops innovative implantable medical devices that will eliminate the need for arteriovenous fistulas in vascular access for hemodialysis. REFERENCES 1. Bello A.K., et al., Epidemiology of haemodialysis outcomes, Nature Reviews, Nephrology, Vol 18, June 2022, 378-395 2. Himmelfarb J., et al., The current and future landscape of dialysis, Nature Reviews, Nephrology, Vol 16, Oct 2020, 573-585 3. Agarwal A.K. et al., Innovations in vascular access for hemodialysis, Kidney International (2019) 95, 1053-1063 4. Allon M., Vascular Access for Hemodialysis Patients – New Data Should Guide Decision Making, American Society of Nephrology, CJASN Vol 14 June, 2019 5. Al-Jaishi A.A. et al., Complications of the Arteriovenous Fistula: A Systematic Review, J Am Soc Nephrol 28: 1839-1850, 2017 6. United States Renal Data System, Annual data report, 2020, End Stage Renal Disease, Chapters 1 and 3 7. Mallios A. et al., Early results of percutaneous arteriovenous fistula creation with the Ellipsys Vascular Access System, Journal of Vascular Surgery, 2018 8. Zemela M.S., et al., Real-World Usage of the WavelinQ EndoAVF System, Ann Vasc Surg. 2021 Jan; 70:116-122 9. Ebner A. et al., Minimally Invasive Sutureless Anastomosis of an AV Hemodialysis Graft, Endovascular Today, November 2014

View contact profiles from Dialyfix